Dr. Stephen Liu, MD, Associate Professor of Medicine, Director of Thoracic Oncology and Director of Developmental Therapeutics at the Lombardi Comprehensive Cancer Center of Georgetown University discusses updated results from a study of patients with RET fusion–positive NSCLC enrolled in the ARROW study, evaluating the efficacy of GAVRETO (pralsetinib) that was presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.
Dr. Stephen V. Liu, MD, is an Associate Professor of Medicine, Director of Thoracic Oncology and Director of Developmental Therapeutics at the Lombardi Comprehensive Cancer Center of Georgetown University.A Pittsburgh native, Dr. Liu graduated cum laude at Johns Hopkins University with a major in Biology and a minor in Film and Media Studies, before receiving his M.D. at the University of Maryland. He completed his Internal Medicine training at the University of Pennsylvania and a dual fellowship in Hematology and Oncology at the University of Southern California, after which he received further specialized training in genomic medicine at the Translational Genomics Research Institute (TGen) under Dr. Daniel Von Hoff. Dr. Liu has been part of the Thoracic Oncology section and the Experimental Therapeutics Program of Georgetown University since 2013. He is a board-certified medical oncologist with expertise in thoracic malignancies including lung cancer, thymic malignancies and mesothelioma. Dr. Liu has a research focus on the development of novel therapeutic agents and innovative combinations for the treatment of advanced thoracic malignancies. He leads the Thoracic Oncology section and the Phase I Developmental Therapeutics group. His work has been published in journals such as the New England Journal of Medicine, Journal of Clinical Oncology, Journal of Thoracic Oncology, Lancet Oncology, Cancer Discovery and Clinical Cancer Research. He is actively involved in post-graduate education and has been awarded multiple teaching awards for his efforts. In addition to leading national and global clinical trials for the treatment of lung cancer, Dr. Liu has also served as the Chief Editor for Frontiers in Thoracic Oncology since 2014.
Listen on Soundcloud.